Diagram 2.1 Epigenetic dysregulation of the metabolic signaling pathways that control cell growth, survival, and chemoresistance mechanisms in DLBCL. Our previous studies have shown that deregulated NF-kB, NFAT, and STAT3…
Fig. 9.1 Types of dedicated breast PET scanners. (a) Positron emission mammography (PEM). (b) Fully tomographic dedicated breast PET with dual-plate detector rotating around the breast. (c) Fully tomographic dedicated…
Grade At rest In operation 0.5 pe 5.5 m 0.5 pe 5.5 A 3520 20 3520 20 B 3520 29 352,000 2900 C 352,000 2900 3,520,000 29,000 D 3,520,000 29,000…
Imaging system Isotope Radiotracer Applied animal model Reference SPECT 99mTc 99mTc-BTAP-AnnexinV Atrial thrombi {Stratton, 1995 #4} {Narula, 2001 #5} 99mTc-HYNIC-Annexin V Jurkat T-cell lymphoblasts {Blankenberg, 1999 #3} {Blankenberg, 1999 #3}…
Fig. 6.1 Constructions of guidance documents by FDA concerning medical imaging drug development and radioactive drug clinical research 6.3.1.3 Clinical Trial Network and Standardization Accordingly, more and more quality assurance…
Fig. 12.1 Panel (a) illustrates the pattern of spontaneous systemic metastases that can arise heterogeneously in mice within a month or more after surgical resection of an established primary orthotopic…
Fig. 11.1 Schema for testing agents through the Pediatric Pre-clinical Testing Program (PPTP). Adapted from reference [68] Standard Cytotoxic Agents Responses to standard cytotoxic agents (vincristine, cyclophosphamide, actinomycin D, cisplatinum,…
Fig. 19.1 Representative image of a spheroid showing the key features. MCF7 cells seeded at 5000 cells per well in a 96-well ULA plate exhibited a tight spheroid after 96…
Fig. 15.1 (a) Human pancreatic-cancer-patient tumor with RFP and GFP stromal cells. Image was obtained with the Olympus FV1000. Green arrows indicate GFP stromal cells from GFP mouse. Red arrows…
Fig. 8.1 Three unique PDX models of early-stage, well-differentiated, androgen-responsive prostate cancer, respectively, all expressing AR and PSA [22, 37] The significant expansion of the number of PDXs for prostate…
